Morgan Stanley has issued a report on Boston Scientific's BSX presentation of Promus Elements at its ACC analyst meeting.
Morgan Stanley writes, "In our view, increased investor confidence in profitability improvement is the most important consequence of the successful PLATINUM trial, though the potential for additional stent share gains is also a nice opportunity. More than 60% of the company's planned 400 bps improvement in gross margin over the next several years is tied to Promus Element conversion."
BSX has an Equal-weight rating and traded at $7.23 at closing yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in